Revive Therapeutics (TSE:RVV) has released an update.
Revive Therapeutics has announced promising research showcasing psilocybin’s potential as a treatment for stroke, highlighting its neuroprotective effects in animal studies. This adds momentum to Revive’s diverse psilocybin-based pharmaceutical program, aimed at addressing neurological and mental health disorders.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
